Drug intelligence / Profile preview

NM-8070

Development stage: Unknown
Lead developer: NovelMed Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Intravitreal

Overview

NM-8070 is a monoclonal antibody developed as an inhibitor of complement component C3. It acts by inhibiting the activity of C3, thereby blocking the complement cascade and reducing inflammation. The drug is being investigated for its potential to treat eye diseases and inflammatory conditions, particularly those involving complement-mediated tissue damage. Preclinical data suggest that NM-8070 can block systemic inflammatory responses associated with procedures such as cardiopulmonary bypass or stenting[1][3]. The developer is NovelMed Therapeutics.

Other names: NM8070NM-8070NM 8070

Targets

Beyond the preview

Go deeper on NM-8070.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NM-8070.

Explore the full profile